ENLV Enlivex Therapeutics, Ltd.: Net earnings per share for the last 12 months

Enlivex Therapeutics (ENLV) maintains flexibility through the outsourcing of production and testing, which minimizes capital expenditures. The GURU.Markets website features this chart, where the annual EPS (TTM) change reaches 3869.90, reflecting the current metric. Efficiency is bolstered by alliances with clinics treating sepsis with Allocetra and the development of a therapy ecosystem under the strict supervision of the FDA and EU regulators.
Enlivex Therapeutics, Ltd. - analytical breakdowns and key metrics (ENLV)

The annual growth rate of net income per share measures business efficiency dynamics, allowing investors to assess the actual speed of capital expansion relative to previous periods. For Enlivex Therapeutics (ENLV), the current EPS YoY TTM growth trend will serve as a key indicator during the commercialization of Allocetra, as the transition to sepsis therapy sales directly transforms the company's fundamental value into real profit.